Michael Weissel, MD; Doris Kerö, MD; Wolfgang Woloszczuk, PhD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: In their recent article, Stall and colleagues (1) conclude that thyroxine-treated women with low serum thyrotropin levels lose bone mineral from the spine more rapidly than do women without known thyroid disease. We are, however, somewhat at loss in evaluating the clinical importance of this elegant study.
Patients with differentiated thyroid cancer (follicular or papillary) are treated with doses of L-thyroxine that are meant to suppress thyrotropin secretion even after thyrotropin-releasing hormone (TRH) stimulation. The rationale behind the use of this therapeutic procedure is the fear that thyrotropin can stimulate the growth or activity of metastases or
Weissel M, Kerö D, Woloszczuk W. Effect of L-Thyroxine on Bone Mass. Ann Intern Med. ;114:339–340. doi: 10.7326/0003-4819-114-4-339_2
Download citation file:
Published: Ann Intern Med. 1991;114(4):339-340.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use